Dietary polyphenols in pediatric obesity and cardiometabolic risk: mechanisms and clinical evidence

Valeria Calcaterra1,2, Hellas Cena3,4, Maria Vittoria Conti3

  • 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Insights

Dietary polyphenols show promise for improving cardiometabolic health in pediatric obesity by influencing inflammation and metabolism. Evidence supports polyphenol-rich diets, but more pediatric trials are needed for isolated polyphenol supplementation.

Area of Science:

  • Nutrition Science
  • Pediatric Health
  • Cardiovascular Research

Background:

  • Pediatric obesity is a significant global health issue linked to early cardiometabolic problems like insulin resistance and inflammation.
  • Dietary polyphenols, found in plant-based foods, possess antioxidant and anti-inflammatory properties that may counteract these issues.

Purpose of the Study:

  • To review the current evidence on dietary polyphenols' role in pediatric obesity and associated cardiometabolic risks.
  • To explore the biological mechanisms by which polyphenols impact oxidative stress, inflammation, metabolism, vascular function, and gut microbiota.
  • To assess observational and clinical data on polyphenol intake in children and adolescents.

Main Methods:

  • Narrative overview of existing scientific literature.
  • Examination of biological pathways influenced by polyphenols.
  • Review of observational studies and clinical trials in pediatric populations.

Main Results:

  • Polyphenols appear to modulate key factors in pediatric obesity, including oxidative stress, inflammation, and metabolic processes.
  • Observational data links polyphenol-rich diets, particularly Mediterranean-style, with better weight and cardiometabolic profiles in youth.
  • Limited and varied pediatric clinical trials hinder definitive conclusions on efficacy and safety.

Conclusions:

  • Dietary polyphenols are biologically relevant to cardiometabolic health in pediatric obesity.
  • Current evidence favors whole food-based dietary patterns over isolated polyphenol supplements.
  • Further large-scale pediatric trials are essential to establish clinical relevance and long-term benefits.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...